Abstract
The gut microbiota in early life, when critical immune maturation takes place, may influence the immunogenicity of childhood vaccinations. We assessed the association between mode of delivery, gut microbiota development in the first year of life, and mucosal antigen-specific immunoglobulin G (IgG) responses against pneumococcal and meningococcal conjugate vaccination at ages 12 and 18 months, respectively, in a prospective birth cohort of 120 infants. Birth by natural delivery was associated with higher IgG responses against both vaccines, which for the anti-pneumococcal IgG response could be explained by a gut microbial community composition with high abundances of Bifidobacterium and Escherichia coli in the first weeks of life. High E. coli abundance in the same period was also associated with higher anti-meningococcal IgG responses. Our results suggest that associations between mode of delivery and antibody responses to routine childhood vaccines are mediated by gut microbiota development.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.trialregister.nl/trial/3821
Funding Statement
This work was funded by the Netherlands Organization for Scientific Research, Chief Scientist Office/NHS Research Scotland, Spaarne Gasthuis, University Medical Center Utrecht, Dutch Ministry of Health, Welfare and Sport and the Strategic Program of the National Institute for Public Health and the Environment (SPR). No other external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
METC Noord-Holland (M012-015, NTR3986), Dutch committee on research involving human subjects
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Co-senior authors
Data Availability
Sequence data that support the findings of this study have been deposited in the NCBI Sequence Read Archive (SRA) database with BioProject ID PRJNA481243, and PRJNA555020.
